Ethypharm is a specialty pharmaceutical company with European roots, focused on specific Central Nervous System (CNS) diseases and conditions, and on adding value to medicines used in Critical Care situations.
Discover Ethypharm at a glance
Many of our products are indicated for sensitive situations in which patients either suffer from debilitating conditions such as chronic pain or addiction, or are in a critical state.
All around the world, Ethypharm employees are engaged daily to make the difference for patients’ lives by ensuring that people in need are able to receive the right treatment at the right time and with the right support.
Ethypharm is deeply engaged in the CNS and Critical Care areas, where our medicines treat patients today and our teams work on innovative solutions for tomorrow. Willing to grow beyond our recognised positions in the treatment of severe pain and opioid dependency, we are constantly screening opportunities in search for those which will respond to unmet needs in our 2 core therapeutic areas.
Ethypharm is a rapidly transforming company, with a clear strategy and significant growth ambition. Our teams are constantly looking for opportunities to develop our product portfolio, selectively enlarge our geographical coverage and enrich our development pipeline. We are extremely open to discussing potential partnerships. Get to know our R&D and business development (BD) teams and come discuss with us!
Ethypharm obtains marketing authorisations for the first Immediate Release orodispersible tablets of morphine in Germany, France and the United Kingdom.
On December 2nd, 2021 – Ethypharm announced having successfully used a European decentralized procedure to obtain its marketing authorisations (MA) for the 1st Immediate-Release orodispersible tablets of morphine in a broad range of dosages. This full in-house development will help Ethypharm to respond to some patients’ specific needs in the field of pain in the three largest European morphine markets: Germany, France and the United Kingdom.
Read the full press release in our newsroom
NB: By clicking on this link, you will be redirected to an external website
Ethypharm consolidates its European presence with the integration of Altan, now led by Manuel Casegas as its General Manager
On October 14th, 2021 – Ethypharm successfully completed the acquisition of Altan and has now welcomed into the group all of its employees. Led by Manuel Casegas, this new affiliate gives Ethypharm a direct presence in Spain and expands its hospital injectables portfolio and R&D pipeline.
Read the full press release in our newsroom
NB: By clicking on this link, you will be redirected to an external website
Ethypharm is growing fast and is always looking to enrich its teams with new talented individuals. We encourage you to visit this site regularly and to follow Ethypharm on LinkedIn to read our latest updates and stay informed about our job opportunities.
Linked